Diabetes mellitus is a major public health problem and its’ prevalance is contuniously rising especially in developed or developing countries. According to World Health Organization (WHO) data the prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030 (1). Despite of improved treatment options for both diabetes mellitus and other associated risk factors, diabetic nephropathy is still a major problem causing increased morbidity and mortality as the increase in total number of diabetic patients finds a reflection in increased prevalence of diabetic patients in end stage renal disease (ESRD) population. There are some studies reporting decreased incidence of diabetic nephropaty in developed countries as a result of better glycemic control and agressive treatment of hypertension with new generation antihypertensives (2). However total number of diabetic nephropathy patients seems to be increasing as a result of increased numbers of diabetic patients and diabetes has become the primary cause of ESRD in the developed countries. Approximately 44% of new patients entering dialysis in the United States are diabetics. In the United States, approximately 20.8 million people, or 7.0% of the population, are estimated to have diabetes, with a growing incidence. Roughly one third of this population, 6.2 million, is estimated to be undiagnosed with type 2 diabetes (3, 4). Similar to these findings prevalence of diabetic nephropahty also increases in in developing countries For example, according to Turkish Society of Nephrology data prevalence of diabetic ESRD patients increased form 7% to 32.5% from 1991 to 2008. A similar trend was also observed for hypertensive nephropathy which raised from 6.3% to 26.8% (5). This hypertensive population is important as according to some previous reports, only one third of essential hypertension patients has normal blood glucose metabolism at diagnosis (6). So it is possible that prevalence of pure diabetic or pure hypertensive nephropathy is lower than predicted but the combination of these two pathological condition is very high in otherwise healthy and ESRD populations.
2. Risk factors
Multiple risk factors for development of diabetic nephropathy were defined. Most important of these seems to be the duration of diabetes mellitus. 20-30% of type I diabetics are supposed to have clinically significant renal involvement (microalbuminuria) after 20 years duration and 15-20% develop ESRD after an additional 10 year (7, 8). These durations are not well defined for type 2 diabetics. 5-25% of these patients might have clinically significant renal failure or even ESRD (1%) at time of diagnosis and approximately 20-30% reach ESRD at 20 years duration (9). The impact of age at time of diabetes diagnosis on development of renal failure is not clear. Among patients with type 2 diabetes, increasing age, along with increasing duration of diabetes was reported to be associated with increased risk for developing albuminuria (10). However some contradicting studies report that, patients who developed diabetes prior to age 20 had a higher risk of progressing to end-stage renal disease (25 versus 5 per 1000 patient years at risk) (11). For type 1 diabetes, the risk of developing ESRD was reported to be very low for patients diagnosed prior to age 5; however at older ages, the relationship of age to progression to ESRD is uncertain (12, 13).
Poor glycemic control is another important risk factor for development of diabetic renal involvement. The Diabetes Control and Complications Trial (DCCT) demonstrated that interventions that improve glycemic control in patients with type 1 diabetes mellitus reduce the risk of development and slow the progression of diabetic microvascular disease, and may also protect against the occurrence of macrovascular disease (14). The United Kingdom Prospective Diabetes Study (UKPDS), a study of over 4000 patients with prolonged follow-up, suggests that strict control also results in a reduced risk of microvascular disease in patients with type 2 diabetes (15).
Hypertension, another important risk factor, is very common in diabetic patients. In fact hypertension is a cause and also a result of diabetic renal disease. Among those with type 1 diabetes, the incidence of hypertension rises from 5% at 10 years, to 33% at 20 years, and 70% at 40 years (16). The blood pressure typically begins to rise within the normal range about three years after the onset of microalbuminuria. Ultimately, the incidence of hypertension is approximately 15 to 25% in all patients with microalbuminuria and 75 to 85% in those with overt diabetic nephropathy (17). On the other hand type 2 diabetic patients have different characteristics. Most of them already have hypertension, even without renal involvement/microalbuminuria at the time of diagnosis (18). Also essential hypertension patients have some glucose metabolism abnormalities including insukin resistance without overt diabetes at time of diagnosis (6).
Approximately one-half of patients with type 1 diabetes of less than five years duration have an elevated glomerular filtration rate (GFR) that is 25 to 50 percent above normal and this situation was reported to have negative effects on disease progression (23). If GFR is above 150 mL/min risk for developing microalbuminuria significantly increases. In one prospective study, for example, patients with type 1 diabetes and a GFR above 125 mL/min had a risk of developing microalbuminuria within 8 years of approximately 50 percent versus only 5 percent in patients with a lower GFR that was similar to that seen in nondiabetics (23).
Some genetic susceptibilities for developing diabetic renal disease were also reported. Most important of these factors are race, family tendencies and ACE gene polymorphisms (24-28). Considering gene polymorphisms; in patients with type 2 diabetes, the ACE/DD polymorphism was reported to associate with an increased risk for the development of diabetic nephropathy, more severe proteinuria, greater likelihood of progressive renal failure, and mortality on dialysis (26-28).
Development of diabetic nephropathy depends on different pathogenic processess. Major of these pathyways will be summarized below
Glomerular hyperfiltration: Studies in experimental animals indicate that dilatation of the afferent (precapillary) glomerular arteriole plays an important role in the hyperfiltration response, by raising both the intraglomerular pressure and renal blood flow (29). Some hormonal factors including insulin-like growth factor I (IGF-1), atrial natriuretic factor and sex hormones were speculated to have effects on hyperfiltration. Most important of these seems to be IGF-1 which induces hyperfiltration, renal vasodilatation and hypertropy in experimental models (30). Increased intracellular sorbitol accumulation, hyperglycemia, glycosylation endproducts and increased sodium reabsorption and tubuloglomerular feedback also has effects on glomerular hyperfiltration
Hyperglycemia and AGEs: Hyperglycemia is known to have a direct effect on mesangial expansion and injury, a result possibly secondary to increased matrix production or glycosylation of matrix proteins. Glycosylation of tissue proteins also may contribute to the development of diabetic nephropathy. Chronic hyperglycemia causes nonenzymatic glycosylation of free amino acids on circulating or tissue proteins and this process forms reversible early glycosylation products and later irreversible advanced glycosylation end products (AGEs). Circulating AGE levels are increased in particularly diabetics with renal insufficiency, because AGEs are normally excreted in the urine. The net effect is tissue accumulation of AGEs, in part by crosslinking with collagen, which can contribute to the associated renal and microvascular complications (31, 32).
Prorenin: A recent experimental model has reported a possible pathogenic role for prorenin in the development of diabetic nephropathy in which prolonged prorenin receptor blockade prevented the development of nephropathy without alterin angiotensin II activity (33).
Proinflammatory cytokines and growth factors: A group of proinflammatory, profibrotic cytokines and growth factors were speculated to have effects on diabetic nephropathy pathogenesis. Most important of these are vascular endothelial growth factor (VEGF), transforming growth factor – beta (TGF-ß). Experimental models reported that VEGF blockade improves albuminuria in diabetic nephropathy (34). Similarly the combination of an anti-TGF-beta antibody and an ACE inhibitor completely normalized proteinuria in experimental diabetic nephropathy models (35).
Proteinuria: Final result of above mentioned pathogenic factors is proteinuria. Normal protein discharge in urine is lower than 30 mg/day for albumin and 150 mg/day for total protein. Microalbuminuria (30-300 mg/day) is a critical treshold for diabetic nephropathy and after this stage untreated patients usually develop overt proteinuria (> 300 mg/day microalbuminuria). Proteinuria was reported to induce inflammation, fibrosis, and it is also have direct tubular toxicity which all promote development of diabetic nephropathy
4. Histopathological changes
All components of renal infrastructure can be affected by diabetic nephropathy. Some of these changes are specific for diabetes, some not. Most common and important changes are capillary basal membrane thickening, diffuse glomerulosclerosis and nodular glomerulosclerosis (Kimmelstiel – Wilson nodules). Nodular glomerulosclerosis was described by Kimmelstiel and Wilson in 1936. These nodules are eosinophilic and PAS positive hard masses which are located in the central regions of peripheral glomerular lobules. They appear to be of mesengial origin and when they are pathogomonic for diabetic nephropathy however they are not universal and found only in 10-40% of patients. The diffuse mesengial lesions are more frequent than nodular glomerulosclerosis and present in 50-90% of patients. They include increased mesengial matrix, basala membrane thickening, capillary narrowing, hyalinization and periglomerular fibrosis. Afferent and efferent arteriolar hyalnization is highly specific for diabetic nephropathy, on the other hand only afferent arteriol involvement is a finding of hypertensive nephrosclerosis.
5. Clinical manifestations and natural history
Clinical stages of type 1 diabetes mellitus renal involvement is summarized in Table-1. These stages are also accepted for type 2 diabetic patients however they might not always follow these steps (36). ESRD is not the only major consequence of diabetic nephropathy but patients have increased risk of cardiovascular disease, morbidity and mortality even in the early stages of nephropathy. Microalbuminuria (30-300 mg/day albuminuria) is the first clinical sign of diabetic nephropathy and this situation is highly associated with other complications of diabetes like cardiovascular disease and retinopathy. 24 hour urine or spot urine albumin / creatinine ratios should be used for microalbuminuria follow-up. Overt proteinuria is defined as >300 mg/day albuminuria and at this stage total protei,n loss in urine might exceed 1g/day. 5-7 years after development of overt proteinuria these patients usually develop ESRD.
6. Diagnosis and differential diagnosis
Proteinuria developing in a diabetic patient is an important marker for diabetic nephropathy however in case of atypical presentation renal biopsy might be indicated. A typical diabetic nephropathy presentation is a type 1 diabetes history for at least 10 years, presence of retinopathy, previous microalbuminuria, no macroscopic hematuria and microscopically inactive urinary sediment. Type 2 diabetic patients might not have this kind of a clinic and as previously mentioned 5-25% of these patients might have clinically significant renal failure or even ESRD (1%) at time of diabetes diagnosis (9). In case of atypical presentation a renal biopsy is usually indicated. Possible atypical presentations are as follows; short diabetes duration (> 10 yrs for type 1 diabetics), no previous retinopathy, overt proteinuria without previous microalbuminuria, macroscoic hematuria, red cell or leucocyte casts, presence of systemic manifestations of any other disease that also can involve kidneys like collagen tissue disorders, amyloidosis etc, rapid decline in renal function without significant proteinuria. Long diabetes duration, previous retinopathy and microalbuminuria might not always be present in type 2 diabetics so in these patients presence of glomerulonephritis clinical features or any other systemic disease with possible renal involvement are biopsy indications.
|1. Nephro-megaly and hyper-filtration stage||At diagnosis||Increased||Reversible albuminuria||No significant finding||Increased renal size||Glomerular hypertrophy|
|2. Latent stage||2-5 years||Normal/Increased||No significant finding||No significant finding||No significant finding||Increased basal membrane thickness|
|3. Incident diabetic nephropathy stage||5-15 years||Normal/Increased||Microalbuminuria (30-300 mg/day)||No significant finding||Hypertension||Increased basal membrane thickness and mesengial expansion|
|4. Overt diabetic nephropathy stage||10-25 years||Decreasing progressively||Overt proteinuria||Increased creatinine||Hypertension and significant nephropathy||Diffuse/nodular glomerulosclerosis|
|5. End stage renal disease stage||15-30 years||Decreased||Overt proteinuria||Uremia||Hypertension and significant nephropathy||Glomerulosclerosis|
Diabetic patients are also prone to some renal diseases or complications which might need to be differentialy diagnosed. Almost every form of glomerular diseases were reported in diabetic nephropathy patients however membranous nephropathy is the most common one. Papillary necrosis, renovascular diseases (arterial or venous), bladder autonomic neuropathy, acute or chronic pyelonephritis, radiocontrast nephropathy and renal tuberculosis should always be kept in mind while evaluating a diabetic patient with renal findings.
7. Treatment and prevention of diabetic nephropathy
Strict glycemic control decreases development of diabetic nephropathy in both type 1 and 2 diabetics. Intensive insulin therapy partially reverse the glomerular hypertrophy and hyperfiltration, delay the development of microalbuminuria, reduce the onset or progression of diabetic nephropathy compared to less intensive therapy, stabilize or decrease protein excretion in patients with microalbuminuria (14, 15, 37, 38). Intensive glycemic not only slow or even prevent development of diabetic nephropathy but also decrease morbidit and mortality ferom other diabetic complications. However the less prominent benefit from strict glycemic control in overt diabetic nephropathy indicates that factors other than hyperglycemia contributes to the glomerular injury. Reducing the intraglomerular pressure with dietary protein restriction or antihypertensive therapy with an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) can minimize progression of or even prevent glomerular disease in the absence of glycemic control. There is now clear evidence that antihypertensive therapy (particularly with RAS blockers) and perhaps protein restriction can reduce the rate of progression in patients with type 1 diabetes and overt nephropathy.
Hypertension increases rate of diabetic nephropathy progression. DCCT and UKPDS trialsdemonstrated that strict blood pressure control decreases microalbuminburia and macroalbuminuria development by 29% and 39% respectively in 6 years follow-up period (14, 15). WHO and JNC advises to keep blood pressure below 130/80 mmHg in diabetic patients. In JNC-VII quideline even a lower level (125/75 mmHg) was proposed for prevention and/or slowing diabetic nephropathy progression (39). ACEI preference in diabetic patients is also recommended in these quidelines. ACEI not only decrease intraglomerular pressure (so decrease proteinuria) by their hemodynamic effects but also decrease glomeruler size and fibrotik process. ACEI were also reported to increase negative charge of basal membrane and so decrease proteinuria. ARBs could also be used alone or in combination with ACEI for increasing nephroprotection (40, 41). Nondihydropyridine class calcium antagonists (NDHCB) are also recommended as a combination with RAS blockers. In BENEDICT trial it was demonstrated that ACEI-NDHCB combination might delay development of microalbuminuria in hypertensive diabetic patients without proteinuria (42). Salt intake should be restricted (< 70 mEq/day) for a beter antirpoteinuric effect as salt seems to blunt effects of both RAS blockers and NDHCB (43, 44). Aldosterone antagonists were also reported to reduce proteinuria when used alone, and to have an additive effect on proteinuria when used in combination with an ACE inhibitor or an ARB in both type 1 and type 2 diabetes (36, 45). Further blood pressure reduction may partially explain the beneficial effect, although an anti-inflammatory mechanism has also been proposed (46). However hyperkalemia in combination treatment ACEI/ARB and aldosterone antagonists) is a significant problem especially in advanced diabetic nephropathy.
Low protein diet decreases hyperfiltration in early stages of diabetic nephropathy and also could slow down GFR loss. However very low protein diets (< 0.6/g/kg/day) could cause malnutrition which is an important mortality risk factor in ESRD population so 0.8 g/kg/day protein diets and essential amino acid supplementations are usually recommended (47).
Hyperlipidemia should also be screened in diabetic patients and must be treated with statins or fibrats if needed. Diabetic patients without hypertension but under simvastatin treatment were reported to have a 25% decrease in microalbuminuria levels (48).
8. Renal replacement treatment in diabetic esrd patients
Diabetic patients usually need renal replacement therapy (RRT) in earlier stages of renal failure. It was reported that nondiabetic patients start receiving RRT when GFR falls below 10 ml/min but on the other hand diabetics need RRT with higher GFR (15-20 ml/min) levels (49). These patients are prone to hypervolemia and lung edema due to accompanying cardiac problems and malnutrition due to proteinuria and dietary restrictions. Diabetic patients developing diuretic resistant edema might need ultrafiltration and start RRT even with higher GFR values.
Patient survival in diabetics on maintenance dialysis is lower than that seen in nondiabetics with end-stage renal failure due to chronic glomerular disease or hypertension (50). As noted in the 2005 USRDS database, only approximately 25 percent of patients with diabetes survived five years after initiation of dialysis and cardiovascular disease is the most common cause of death, accounting for more than one-half of cases (50).
Renal transplantation is a choice of RRT in diabetic ESRD patients however five year survival is clearly lower than other ESRD patients ranging from 75% to 83% (51). Despite of this poor outcome, transplantation still result in decreased extrarenal vascular diseaseand better quality of life compared with either hemodialysis or peritoneal dialysis (51).
Making choice of dialysis modality in diabetic patients is similar with nondiabetic patients. Comorbid conditions, home situation, independence and motivation of the patient, ability to tolerate volume shifts, patients’ desire, status of the vasculature and/or abdomen should be evaluated for each patient. The relative effect of hemodialysis and CAPD on survival in diabetic patients is uncertain. Initial reports suggested that CAPD was associated with a better outcome (52). However data from the USRDS case-mix study suggest that mortality may actually be increased in diabetic patients receiving CAPD . A subsequent very large study attempted to assess the impact of multiple risk factors, including diabetes, on survival after initiation of either hemodialysis or peritoneal dialysis. Utilizing data from 398,940 patients who initiated dialysis between the years 1995 to 2000. Mortality risk was significantly higher on hemodialysis than PD among younger diabetics with no comorbidity. By comparison, hemodialysis was associated with a lower mortality risk in older diabetics with either no comorbidity or a baseline comorbidity.
Wild S. Roglic G. Gren A. et al. 2004Global prevalence of diabetes. Diabetes Care ; 27 1047 53
Wolf G. 2004New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest ; 34 785 96http://www.usrds.org/adr.htm
American Diabetes Association. 2007Total Prevalence of Diabetes and Pre-diabetes, Available at http://www.tsn.org.tr http://www.diabetes.org/diabetes-statistics/prevalence.jsp
Garcia-Puig J. Ruilope L. M. Lugue M. et al. 2006Glucose metabolism in patients with essential hypertension. Am J Med ; 119 318 26
Orchard T. J. Dorman J. S. Maser R. E. et al. 1990Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes ; 39: 1116 EOF 24 EOF
Krolewski M. Eggers P.W. Warram J.H. 1996.Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int ; 50:2041
Adler A. I. Stevens R. J. Manley S. E. Bilous R. W. 2003Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int ; 63: 225 EOF 232 EOF
Tapp R. J. Shaw J. E. Zimmet P. Z. et al. 2004Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis ; 44:792.
Pavkov M. Bennett P. H. Knowler W. C. et al. 2006Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA ; 296: 421 EOF 6 EOF
Finne P. Reunanen A. Stenman S. et al. 2005Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA ; 294: 1782 EOF 7 EOF
Svensson M. Nystrom L. Schon S. Dahlquist G. 2006Age at onset of childhood-onset type 1 diabetes and the development of end-stage renal disease: a nationwide population-based study. Diabetes Care 29: 538 EOF 42 EOF
The Diabetes Control and Complications Trial Research Group. 1993The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med ; 329:977.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). 1998UK Prospective Diabetes Study (UKPDS) Group. Lancet ; 352:837.
Epstein M. Sowers J.R. 1991.Diabetes mellitus and hypertension. Hypertension 1992; 19:403
Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care ; 14 Suppl 4: Mogensen C. E. Hansen K. W. Pedersen M. M. Christensen C. K. 13 EOF 26 EOF
Hypertension in Diabetes Study (HDS). 1993I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens ; 11:309.
Gelber R. P. Kurth T. Kausz A. T. et al. 2005Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis ; 46: 871 EOF 80 EOF
Ejerblad E. Fored C. M. Lindblad P. et al. 2006Obesity and risk for chronic renal failure. J Am Soc Nephrol ; 17: 1695 EOF 702 EOF
Morales E. Valero M. A. Leon M. et al. 2003Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis ; 41: 319 EOF 27 EOF
Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol. Zoja C. Corna D. Gagliardini E. et al. 2010Nov;299(5):F 1203 11
Rudberg S. Persson B. Dahlquist G. 1992Increased glomerular filtration rate as a predictor of diabetic nephropathy An 8year prospective study. Kidney Int ; 41:822.
Pettitt D. J. Saad M. F. Benneth P. H. et al. 1990Familial predisposition to renal disease in two generations of Pima Indians with type 2 diabetes mellitus. Diabetologia 33: 438 EOF 43 EOF
Familial clustering of cardiovascular disease in patients with insulin dependent diabetes and nephropathy. N Eng J Med 7: 2627-35, Earle K. Walker J. Hill C. et al. 1996
Jeffers B. W. Estacio R. O. Raynolds M. V. et al. 1997Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int ; 52: 473 EOF 7 EOF
Yoshida H. Kuriyama S. Atsumi Y. et al. 1996Angiotensin I converting enzyme gene polymorphism in non-insulin-dependent diabetes mellitus. Kidney Int ; 50: 657 EOF 64 EOF
Kuramoto N. Lizuka T. Ito H. et al. 1999Effect of ACE gene on diabetic nephropathy in NIDDM patients with insulin resistance. Am J Kidney Dis ; 33:276.
Bank N. 1991Mechanisms of diabetic hyperfiltration. Kidney Int 40: 792 EOF 807 EOF
Hirschberg R. Kopple J. D. 1992The growth hormone-insulin-like growth factor I axis and renal glomerular filtration. J Am Soc Nephrol ; 2:1417.
Makita Z. Radoff S. Rayfield E. J. et al. 1991Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med ; 325: 836 EOF 42 EOF
al. Singh A. K. Mo W. Dunea G. at 1998Effect of glycated proteins on the matrix of glomerular epithelial cells. J Am Soc Nephrol ; 9: 802 EOF 10 EOF
Ichihara A. Suzuki F. Nakagawa T. et al. 2006.Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol ; 17:1950
Sung S. H. Ziyadeh F. N. Wang A. et al. 2006Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol ; 17: 3093 EOF 104 EOF
Benigni A. Zoja C. Corna D. et al. 2003.Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol ; 14:1816
Mogensen C. E. Cooper M. E. 2004Diabetic renal disease: from recent studies to improved clinical practice. Diabet Med ; 21 4 17
Shichiri M. Kishikawa H. Ohkubo Y. et al. 2000Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care ; 23 Suppl 2: B21 EOF 9 EOF
. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy 2003. the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA ; 290:2159
Chobanian A. V. Bakris G. L. Black H. R. et al. 2003National Heart, Lung and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Eduv-cation Program Coordinating Committee. Comment in: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of Higgh Blood Pressure: JNC 7 report. JAMA ; 289 2560 72
Lewis E. J. Hunsicker L. J. Clarke W. R. et al. 2001Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with type 2 diabetes. N Eng J Med ; 345 851 8
Brenner B. M. Goper M. E. de Zeeuw D. et al. 2001RENAAL AStudy Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med ; 345 861 9
Ruggenenti P. Fassi A. Ilieva A.P. et al. 2004.Preventing microalbuminuria in Type 2 Diabetes. N Eng J Med ; 351: 1941-51
Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med Bakris G. L. Smith A. 1996 201 EOF 4 EOF
Bakris G. L. Weir M. R. 1996Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link?. Am J Hypertens ; 9: 200S EOF 206S EOF
Rachmani R. Slavachevsky I. Amit M. et al. 2004The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med ; 21: 471 EOF 475 EOF
van den Meiracker A.H. Baggen R.G. Pauli S. et al. 2006.Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens ; 24:2285
Han S. Y. Kim C. H. Kim H. S. et al. 2006Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol ; 17: 1362 EOF 72 EOF
. Tonolo G. Ciccares M. Brizi P. et al 1997.Reduction albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long term simvastatin treatment. Diabetes Care 20: 1891-5
Stein G. Fünfstück R. Schiel R. 2004Diabetes Mellitus and dialysis. Minerva Urol Nefrol ; 56 289 303
United States Renal Data System. 2005.Excerpts from the USRDS annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2006; 47(Suppl 1):S1
Locatelli F. Pozzoni P. Del Vecchio L. 2004Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol ; 15 Suppl 1: S25 EOF 9 EOF
Wolfe R. A. Port F. K. Hawthorne V. M. et al. 19 1990A comparison of survival among dialytic therapies of choice: In-center hemodialysis versus continuous ambulatory peritoneal dialysis at home. Am J Kidney Dis ; 15: 433 EOF 40 EOF
Held P. J. Port F. K. M. Turenne M. N. et al. 1994Continuous ambulatory peritoneal dialysis and hemodialysis: Comparison of patient mortality with adjustment for comorbid conditions. Kidney Int ; 45: 1163 EOF 9 EOF
Vonesh E.F. Snyder J.J. Foley R.N. et al. 2004.The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int ; 66:2389